通化金马：拟投资7000万元设立全资子公司 开展创新药产业并购和布局

Core Viewpoint - Tonghua Jinma (000766) announced the establishment of a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., with an investment of 70 million yuan to support its strategic shift towards becoming an innovation-driven modern pharmaceutical enterprise [1] Group 1 - The investment of 70 million yuan will be funded through the company's own or raised funds [1] - The establishment of the subsidiary is part of the company's strategy to enhance its mergers and acquisitions and layout in the innovative drug industry [1] - This move aligns with the company's overall strategic planning and research and development needs [1]